Simulated effect of pneumococcal vaccination in the Netherlands on existing rules constructed in a non-vaccinated cohort predicting sequelae after bacterial meningitis.
BACKGROUND
Previously two prediction rules identifying children at risk of hearing loss and academic or behavioral limitations after bacterial meningitis were developed. Streptococcus pneumoniae as causative pathogen was an important risk factor in both. Since 2006 Dutch children receive seven-valent conjugate vaccination against S. pneumoniae. The presumed effect of vaccination was simulated by excluding all children infected by S. pneumoniae with the serotypes included in the vaccine, from both previous collected cohorts (between 1990-1995).


METHODS
Children infected by one of the vaccine serotypes were excluded from both original cohorts (hearing loss: 70 of 628 children; academic or behavioral limitations: 26 of 182 children). All identified risk factors were included in multivariate logistic regression models. The discriminative ability of both new models was calculated.


RESULTS
The same risk factors as in the original models were significant. The discriminative ability of the original hearing loss model was 0.84 and of the new model 0.87. In the academic or behavioral limitations model it was 0.83 and 0.84 respectively.


CONCLUSIONS
It can be assumed that the prediction rules will also be applicable on a vaccinated population. However, vaccination does not provide 100% coverage and evidence is available that serotype replacement will occur. The impact of vaccination on serotype replacement needs to be investigated, and the prediction rules must be validated externally.
Commandeur
Arno E
AE
Department of Pediatrics and Infectious Diseases, VU University Medical Center, Amsterdam, The Netherlands.
de Jonge
Rogier C J
RC
Koomen
Irene
I
Spanjaard
Lodewijk
L
van Furth
A Marceline
AM
Terwee
Caroline B
CB
D002648:Child; D002675:Child, Preschool; D003198:Computer Simulation; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D008586:Meningitis, Pneumococcal / Q000150:complications* / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D009422:Nervous System Diseases / Q000453:epidemiology* / Q000517:prevention & control*; D009426:Netherlands / Q000453:epidemiology; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000302:isolation & purification; D014611:Vaccination / Q000706:statistics & numerical data*
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines
Vaccine. 2007 Apr 20;25(16):3085-9
17287048
MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8
18272956
FEMS Immunol Med Microbiol. 2007 Oct;51(1):35-42
17854472
Pediatr Infect Dis J. 1993 May;12(5):389-94
8327300
Pediatr Infect Dis J. 2000 Mar;19(3):187-95
10749457
J Clin Epidemiol. 2008 Nov;61(11):1085-94
19208371
Stat Med. 2000 Feb 29;19(4):453-73
10694730
Pediatrics. 2003 Nov;112(5):1049-53
14595044
Int J Antimicrob Agents. 2008 Sep;32(3):199-206
18378430
J Clin Epidemiol. 2003 Sep;56(9):826-32
14505766
JAMA. 2006 Apr 12;295(14):1668-74
16609088
Microb Drug Resist. 2008 Jun;14(2):101-7
18491947
Pediatrics. 1995 May;95(5):646-56
7536915
Clin Infect Dis. 2009 Jul 15;49(2):e23-9
19522653
J Infect Dis. 2006 Jun 1;193(11):1487-94
16652275
Vaccine. 2008 Jun 19;26(26):3277-81
18456376
Acta Paediatr. 2004 Oct;93(10):1378-85
15499961
Clin Infect Dis. 2008 Dec 1;47(11):1388-95
18959493
Lancet. 2003 Jun 21;361(9375):2139-48
12826449
BMJ. 2009 May 28;338:b605
19477892
Pediatr Infect Dis J. 1995 Jul;14(7):624-5
7567294